Cerapedics

Cerapedics is a privately held medical device company founded in 2005, headquartered in Westminster, Colorado, USA. It has established a commercial-stage presence in the orthopedic bone graft market with its proprietary P-15 peptide technology platform, which is designed to attract and activate osteogenic cells to accelerate bone formation. The company's portfolio includes two FDA-approved products, i-FACTOR for cervical fusion and the recently approved PearlMatrix for lumbar fusion, both supported by rigorous PMA clinical data. Cerapedics operates in a large and growing spinal fusion market, competing on the strength of its clinical evidence and differentiated mechanism of action.

Proprietary P-15 Osteogenic Cell Binding Peptide, a synthetic 15-amino acid sequence that mimics the cell-binding domain of Type I collagen. It is bound to a calcium phosphate scaffold to create a bone graft that actively attaches to and activates osteogenic cells to accelerate new bone formation.

Cerapedics competes in the crowded spinal bone graft market, which includes synthetic grafts, demineralized bone matrices (DBMs), allografts, and growth factor-based products like rhBMP-2. Its key differentiation is the PMA clinical evidence supporting its P-15 technology, a claim only one other product (rhBMP-2) can make. It positions itself against the majority of 510(k)-cleared products by emphasizing superior clinical validation and a targeted, physiologic mechanism of action versus passive scaffolds or potent growth factors.